Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2004

View Archived Issues

Characterization of dual TACE/MMP inhibitor for rheumatoid arthritis treatment

OPi completes restructuring

BioXell and ProSkelia join efforts in osteoporosis drug discovery

Pfizer completes tender offer for Esperion Therapeutics' common shares

GTC restructures

DOR BioPharma updates status of ricin vaccine development program

Dynavax licenses immunotherapy programs to UCB

P&G licenses topical antiinfective technology to GMP Companies

Senju claims new chymase and/or tryptase inhibitors and their use

Pharmacia scientists report novel telomerase inhibitors in a recent patent

Novel androgen receptor agonists under study at Kaken

Kyowa Hakko presents new antidiabetic agents

Dual D2/5-HT1A agonists with potential in Parkinson's disease therapy

New ACAT and LDL oxidation inhibitors reported by Sankyo scientists

Nippon Kayaku claims a novel antineoplastic antibiotic from Streptomyces sp.

Takeda researchers prepare and test triazole-based DPP-IV inhibitors

Genasense NDA accepted for review

Enrollment completed in confirmatory phase III trial of Prestara

Replagal receives Canadian approval

PA-457 IND cleared for initiation of clinical trials

Antares receives milestone payment from Pfizer licensing agreement

Keryx completes acquisition of Access Oncology

Fourth phase II trial for AMD-3100 underway

Update on single-agent Triapine phase II trials

Comparable results in phase II head-to-head study of TA-1790 and Viagra

SPA agreement for PRECISE trial with IL13-PE38QQR, program accepted for FDA CMA Pilot 2 program

Good safety profile found for CAT-192 in diffuse systemic sclerosis

Studies demonstrate efficacy of Tri-Luma in melasma patients

Use of infliximab in the treatment of psoriasis, dermatitis, other conditions reported at AAD

Clinical, other studies of pimecrolimus presented at dermatology congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...